Skip to main content
Clinical Trials/DRKS00026098
DRKS00026098
Recruiting
Not Applicable

Prospective study of prognostic markers of kidney damage in cardiorenal syndrome

niversitätsmedizin Göttingen0 sites170 target enrollmentJanuary 3, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic kidney disease in cardiorenal syndrome
Sponsor
niversitätsmedizin Göttingen
Enrollment
170
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 3, 2022
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversitätsmedizin Göttingen

Eligibility Criteria

Inclusion Criteria

  • Adult patients capable of consent
  • \- Age \= 18 years
  • \- Outpatients able to consent and cooperate
  • \- Written consent to study participation
  • \- Patients with a cardio\-renal risk profile on stable guideline medication for \> 3 months (at least 1 of the following applies):
  • A) Patients for whom SGLT2 inhibitor therapy is planned as part of best clinical practice:
  • Diabetes mellitus II with nephropathy (group 1\)
  • CKD and HFrEF (echocardiographically confirmed) (Group 2\)
  • CKD without diabetes (Group 3\)
  • CKD and HFpEF (Group 7\)

Exclusion Criteria

  • \- Patients who have had a kidney transplant (NTX) or require dialysis
  • \- Chronic renal insufficiency CKD stage\> G4 (\<15 ml / min according to the CKD EPI formula)
  • \- Current acute kidney damage
  • \- Postrenal obstruction
  • \- (Proven) pulmonary hypertension in the context of causes other than heart failure (class 2\)
  • \- pregnancy or breastfeeding
  • \- Circumstances that interfere with the implementation or interpretation of the measured variables, such as severely restrictive respiratory diseases, strongly fluctuating blood pressure values ??and others
  • \- Presence of type I diabetes mellitus
  • \- Active tumor disease
  • \- Inflammatory or autoimmune disease that affects kidney function

Outcomes

Primary Outcomes

Not specified

Similar Trials